

**Drug/Lab****Increase:** bilirubin**Decrease:** neutrophil, platelets, WBC, potassium**NURSING CONSIDERATIONS****Assess:**

- B/P; take frequently if hypertension develops, discontinue if hypertensive crisis occurs
- For symptoms of infection; may be masked by product
- **CNS reaction:** dizziness, confusion
- **HF:** crackles, jugular venous distention, dyspnea during treatment
- **GU status(proteinuria):** nephrotic syndrome may occur; monitor urinalysis for increasing protein level; product should be held if protein  $\geq 2$  g/24 hr; resume when  $< 2$  g/24 hr

**Black Box Warning: Wound dehiscence:**hold for  $\geq 28$  days until incision is healed, discontinue 28 days prior to elective surgery

**Black Box Warning: GI perforation** (constipation, fever, abdominal pain, nausea, vomiting), **serious bleeding** (bleeding from any orifice, stroke, deep vein thrombosis), **nephrotic syndrome**, **hypertensive crisis**; product should be discontinued permanently; surgery should be postponed

- **Thromboembolic events:** monitor for stroke, TIA, MI; usually occurs in geriatric patients who used this product previously
- **Fistulas:** may occur within 6 mo of beginning treatment, may be fatal
- **Pregnancy/breastfeeding:** drug may lead to fetal harm; do not use in pregnancy, do not breastfeed during and for 6 months after last dose; use contraception during and for 6 months after last dose
- **Reversible posterior leukoencephalopathy syndrome (RPLS):** discontinue if this disorder develops (headache, vision changes, seizures, altered mental status); MRI may be ordered, occurs 16 hr-1 yr after beginning treatment

**Evaluate:**

- Therapeutic response: decrease in size of tumors

**Teach patient/family:**

- To avoid hazardous tasks because confusion, dizziness may occur
- To report signs of infection: sore throat, fever, diarrhea, vomiting

**Black Box Warning: Hemorrhage/bleeding:** to report bleeding, changes in urinary patterns, edema, abdominal pain

- To avoid live virus vaccines
- About the need to discontinue product a month before surgery and not to restart until wound is healed
- **Pregnancy/breastfeeding:** that fetal harm may occur, not to breastfeed, not to become pregnant while taking this product or for 6 months after discontinuing treatment; discuss possible infertility with patient

**bezlotoxumab**

(bez' loe-tox' ue-mab)

**Zinplava***Func. class.:* Antidiarrheal*Chem class.:* Monoclonal antibody**ACTION:** Binds to *Clostridium difficile* toxin B**USES:** For *Clostridium difficile* infection (CDI) in patients who are receiving antibacterial treatment of CDI and are at a high risk for CDI recurrence**CONTRAINDICATIONS:** Hypersensitivity**Precautions:** Breastfeeding, pregnancy, heart failure**DOSAGE AND ROUTES**

- **Adult:** IV 10 mg/kg as a single dose

**Available forms:** Sol for inj 25 mg/mL